Influenza – Production of a live attenuated influenza virus vaccine
With a novel method it is possible for the first time to produce a live attenuated influenza A virus vaccine. The method is based on the production of specific mutants of influenza viruses which in vivo are in fact immunogenic, but not pathogenic. Their genome largely corresponds with that of the currently active epidemic strain, allowing their utilisation as attenuated recombinant vaccine against the influenza virus. Due to the particular characteristics of the influenza virus mutants, the application of this vaccine will be possible for children, elderly people and even immunodeficient people.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Sea slugs inspire highly stretchable biomedical sensor
USC Viterbi School of Engineering researcher Hangbo Zhao presents findings on highly stretchable and customizable microneedles for application in fields including neuroscience, tissue engineering, and wearable bioelectronics. The revolution in…
Twisting and binding matter waves with photons in a cavity
Precisely measuring the energy states of individual atoms has been a historical challenge for physicists due to atomic recoil. When an atom interacts with a photon, the atom “recoils” in…
Nanotubes, nanoparticles, and antibodies detect tiny amounts of fentanyl
New sensor is six orders of magnitude more sensitive than the next best thing. A research team at Pitt led by Alexander Star, a chemistry professor in the Kenneth P. Dietrich…
